A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV (NCT07053384)
An Exploratory Phase 1b, Multicenter, Randomized, Open-Label Study to Investigate the Impact of the Administration of Intravenous VH3810109 With or Without Oral Fostemsavir in Combination With Integrase Inhibitor-Based Antiretroviral Therapy on the Viral Reservoir in Adults Living With HIV-1
🩺 Plain-English Summary (8th-Grade Level)
This study investigates the use of VH3810109 with or without FTR to reduce the size and activity of the HIV viral reservoir in two sub-populations of people living with HIV: treatment-naïve adults (Population 1) and treatment-experienced adults currently taking a standard of care (SOC) integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) regimen (Population 2). The study is designed to include the following phases: Randomized Intervention Phase (Step 1), Analytical Treatment Interruption (ATI) Phase (Step 2), and Follow-up Phase (Step 3).
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — Bakersfield, California
Age range: 18 Years to 70 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (41 Sites)
Showing the first 25 of 41 sites.
- GSK Investigational Site — Bakersfield, California
- GSK Investigational Site — San Diego, California
- GSK Investigational Site — Ft. Pierce, Florida
- GSK Investigational Site — Orlando, Florida
- GSK Investigational Site — Chicago, Illinois
- GSK Investigational Site — Kansas City, Missouri
- GSK Investigational Site — St Louis, Missouri
- GSK Investigational Site — New York, New York
- GSK Investigational Site — Cincinnati, Ohio
- GSK Investigational Site — Philadelphia, Pennsylvania
- GSK Investigational Site — Pittsburgh, Pennsylvania
- GSK Investigational Site — Dallas, Texas
- GSK Investigational Site — Dallas, Texas
- GSK Investigational Site — Brussels,
- GSK Investigational Site — Ghent,
- GSK Investigational Site — Aarhus,
- GSK Investigational Site — Hvidovre,
- GSK Investigational Site — Rotterdam,
- GSK Investigational Site — Barcelona,
- GSK Investigational Site — Barcelona,
- GSK Investigational Site — Barcelona,
- GSK Investigational Site — Barcelona,
- GSK Investigational Site — Barcelona,
- GSK Investigational Site — Barcelona,
- GSK Investigational Site — Córdoba,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in HIV Infections
- Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention — Chicago, Illinois
- The Ganchero Intervention for Migrant People Who Inject Drugs From Puerto Rico in New York City — New York, New York
- Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults — Birmingham, Alabama
- Clinical Decision Support for PrEP — Los Angeles, California
- Peer Supported Collaborative Care Mental Health and Substance Use Disorder Care — Baltimore, Maryland
- A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIV — Las Vegas, Nevada
Explore by condition: All HIV Infections clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.